Autoinjectors Market by Usage (Disposable, Reusable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Obesity, Anaphypaxis, Multiple Sclerosis), Route of Administration (SC, IM), Volume (<3ml, >3ml) - Global Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 INCLUSIONS & EXCLUSIONS
• 1.4 STUDY SCOPE
  • 1.4.1 SEGMENTS CONSIDERED
  • 1.4.2 YEARS CONSIDERED
  • 1.4.3 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 RESEARCH DESIGN
  • 2.1.2 SECONDARY DATA
    • 2.1.2.1 Objectives of secondary research
  • 2.1.3 PRIMARY DATA
    • 2.1.3.1 Breakdown of primaries (supply- and demand-side participants)
    • 2.1.3.2 Objectives of primary research
• 2.2 MARKET SIZE ESTIMATION OF AUTOINJECTOR DEVICES
• 2.3 MARKET SIZE ESTIMATION OF AUTOINJECTOR FINISHED FORMULATIONS
  • 2.3.1 INSIGHTS FROM PRIMARY EXPERTS
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 MARKET GROWTH RATE PROJECTIONS
• 2.5 DATA TRIANGULATION
• 2.6 STUDY ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 AUTOINJECTORS MARKET OVERVIEW
• 4.2 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE AND COUNTRY (2023)
• 4.3 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION AND COUNTRY (2023)
• 4.4 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2024 VS. 2030 (USD MILLION)
• 4.5 AUTOINJECTORS MARKET SHARE, BY TECHNOLOGY, 2023
• 4.6 AUTOINJECTOR DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.7 AUTOINJECTOR FINISHED FORMULATIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising prevalence of chronic diseases
    • 5.2.1.2 Increasing regulatory approvals for autoinjectors
    • 5.2.1.3 High demand for biosimilars and biologics
    • 5.2.1.4 Growing adoption of self-administered medicines
    • 5.2.1.5 Government support and favorable reimbursement policies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Focus on needle-free drug delivery systems and prevalence of needle phobia
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Impending patent expiry of biological molecules
    • 5.2.3.2 Launch of technologically-advanced autoinjectors
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Development of autoinjectors for multiple drug viscosities
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 VALUE CHAIN ANALYSIS
  • 5.4.1 VALUE CHAIN ANALYSIS: AUTOINJECTOR DEVICE MANUFACTURERS (PLATFORM PROVIDERS)
  • 5.4.2 VALUE CHAIN ANALYSIS: AUTOINJECTOR FINISHED FORMULATION MANUFACTURERS
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 AUTOINJECTOR PROVIDERS
  • 5.6.2 END USERS
  • 5.6.3 REGULATORY BODIES
• 5.7 REGULATORY ANALYSIS
  • 5.7.1 REGULATORY LANDSCAPE
    • 5.7.1.1 North America
    • 5.7.1.2 Europe
    • 5.7.1.3 Asia Pacific
  • 5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.7.2.1 North America
    • 5.7.2.2 Europe
    • 5.7.2.3 Asia Pacific
    • 5.7.2.4 Rest of the World
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.8.2 BARGAINING POWER OF SUPPLIERS
  • 5.8.3 BARGAINING POWER OF BUYERS
  • 5.8.4 THREAT OF SUBSTITUTES
  • 5.8.5 THREAT OF NEW ENTRANTS
• 5.9 TRADE DATA ANALYSIS
  • 5.9.1 IMPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS)
  • 5.9.2 EXPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS)
• 5.10 TECHNOLOGY ANALYSIS
  • 5.10.1 KEY TECHNOLOGIES
    • 5.10.1.1 Injection mechanism technology
    • 5.10.1.2 Electronic and connectivity solutions
  • 5.10.2 ADJACENT TECHNOLOGIES
    • 5.10.2.1 Wearable drug delivery devices
    • 5.10.2.2 Implantable drug delivery systems
  • 5.10.3 COMPLEMENTARY TECHNOLOGIES
    • 5.10.3.1 Power assistance mechanisms
    • 5.10.3.2 Advanced needle technology
• 5.11 PATENT ANALYSIS
  • 5.11.1 METHODOLOGY
  • 5.11.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
  • 5.11.3 INNOVATION AND PATENT APPLICATIONS
  • 5.11.4 TOP APPLICANTS FOR PATENTS
• 5.12 INDICATIVE PRICING ANALYSIS
  • 5.12.1 AVERAGE SELLING PRICE TREND, BY PRODUCT TYPE
  • 5.12.2 AVERAGE SELLING PRICE TREND, BY USAGE
  • 5.12.3 INDICATIVE AUTOINJECTOR FINISHED FORMULATIONS PRICING ANALYSIS, BY KEY PLAYER
  • 5.12.4 INDICATIVE AUTOINJECTOR FINISHED FORMULATIONS PRICING ANALYSIS, BY REGION
• 5.13 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.14 INVESTMENT AND FUNDING SCENARIO
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.15.1.1 Key stakeholders in buying process for autoinjector devices
    • 5.15.1.2 Key stakeholders in buying process for autoinjector finished formulations
  • 5.15.2 KEY BUYING CRITERIA
    • 5.15.2.1 Key buying criteria for autoinjector devices
    • 5.15.2.2 Key buying criteria for autoinjector finished formulations
• 5.16 IMPACT OF GENERATIVE AI ON AUTOINJECTORS MARKET

6 AUTOINJECTORS MARKET, BY USAGE

• 6.1 INTRODUCTION
• 6.2 DISPOSABLE AUTOINJECTORS
  • 6.2.1 EASE OF USE AND REDUCED RISK OF NEEDLESTICK INJURIES TO PROPEL MARKET GROWTH
• 6.3 REUSABLE AUTOINJECTORS
  • 6.3.1 COST-EFFECTIVENESS, VERSATILITY, AND SUSTAINABILITY TO FUEL MARKET GROWTH

7 AUTOINJECTORS MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 MANUAL AUTOINJECTORS
  • 7.2.1 USER-FRIENDLY DESIGN AND INCREASED PATIENT CONTROL TO AUGMENT MARKET GROWTH
• 7.3 AUTOMATIC AUTOINJECTORS
  • 7.3.1 EASE OF ACCURATE DOCUMENTATION AND COMPREHENSIVE PATIENT RECORDS TO SUPPORT MARKET GROWTH

8 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION

• 8.1 INTRODUCTION
• 8.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION
  • 8.2.1 EASE OF USE, RAPID ABSORPTION, AND SUITABILITY FOR SELF-ADMINISTRATION TO AID MARKET GROWTH
• 8.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION
  • 8.3.1 NEED FOR PRECISE DOSE DELIVERY IN EMERGENCY CLINICAL SETTINGS TO DRIVE MARKET

9 AUTOINJECTORS MARKET, BY THERAPY AREA

• 9.1 INTRODUCTION
• 9.2 RHEUMATOID ARTHRITIS
  • 9.2.1 HIGH DISEASE PREVALENCE AND NEED FOR FREQUENT DOSING TO DRIVE MARKET
• 9.3 DIABETES
  • 9.3.1 LARGE DIABETIC POPULATION AND EASE OF ADMINISTRATION TO STIMULATE DEMAND
• 9.4 MULTIPLE SCLEROSIS
  • 9.4.1 AVAILABILITY OF COST-EFFECTIVE GENERIC ORAL MULTIPLE SCLEROSIS DRUGS TO LIMIT MARKET GROWTH
• 9.5 ANAPHYLAXIS
  • 9.5.1 REQUIREMENT FOR PROMPT INITIAL TREATMENT FOR PATIENTS WITH FOOD ALLERGIES TO FUEL MARKET GROWTH
• 9.6 OBESITY
  • 9.6.1 INCREASING FOCUS ON WEIGHT MANAGEMENT TO BOOST MARKET GROWTH
• 9.7 OTHER THERAPY AREAS

10 AUTOINJECTORS MARKET, BY VOLUME

• 10.1 INTRODUCTION
• 10.2 UP TO 3ML VOLUME AUTOINJECTORS
  • 10.2.1 RISING PREVALENCE OF AUTOIMMUNE DISORDERS AND LONG-TERM CHRONIC DISEASES TO PROPEL MARKET GROWTH
• 10.3 ABOVE 3ML VOLUME AUTOINJECTORS
  • 10.3.1 INCREASING FOCUS ON COMPLEX TREATMENTS WITH HIGH-VISCOSITY DRUGS TO DRIVE MARKET

11 AUTOINJECTORS MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 HOME CARE SETTINGS
  • 11.2.1 COST-EFFECTIVENESS AND INCREASED AVAILABILITY OF HOME CARE SUPPORT SERVICES TO PROPEL MARKET GROWTH
• 11.3 HOSPITALS & CLINICS
  • 11.3.1 TECHNOLOGICAL ADVANCEMENTS AND AVAILABILITY OF REAL-TIME PATIENT DATA TO SUPPORT MARKET GROWTH
• 11.4 AMBULATORY CARE SETTINGS
  • 11.4.1 GROWING DEMAND FOR OUTPATIENT SERVICES TO FUEL MARKET GROWTH

12 AUTOINJECTORS MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 US
    • 12.2.1.1 US to dominate North American autoinjectors market during forecast period
  • 12.2.2 CANADA
    • 12.2.2.1 Rising geriatric population and increasing prevalence of food allergies to propel market growth
• 12.3 EUROPE
  • 12.3.1 GERMANY
    • 12.3.1.1 Favorable government initiatives and regulatory trends to aid market growth
  • 12.3.2 UK
    • 12.3.2.1 High prevalence of allergic conditions and increased incidence of lifestyle diseases to boost market growth
  • 12.3.3 FRANCE
    • 12.3.3.1 High prevalence of diabetes and favorable reimbursement policies to support market
  • 12.3.4 ITALY
    • 12.3.4.1 Rising healthcare expenditure and increasing geriatric population to augment market growth
  • 12.3.5 SPAIN
    • 12.3.5.1 Favorable reimbursement scenario and presence of universal health coverage facility to aid market growth
  • 12.3.6 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 JAPAN
    • 12.4.1.1 Large geriatric population and improved healthcare infrastructure to drive market
  • 12.4.2 CHINA
    • 12.4.2.1 Increasing prevalence of food allergies and anaphylaxis to fuel market growth
  • 12.4.3 INDIA
    • 12.4.3.1 Increasing burden of diabetes and cardiovascular diseases to spur market growth
  • 12.4.4 SOUTH KOREA
    • 12.4.4.1 Increased regulatory approvals and strong clinical pipeline by domestic players to propel market
  • 12.4.5 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 BRAZIL
    • 12.5.1.1 Rising adoption of autoinjectors and growing prevalence of chronic diseases to augment market growth
  • 12.5.2 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 GCC COUNTRIES
    • 12.6.1.1 High healthcare spending capacity and favorable regulatory scenario to drive market
  • 12.6.2 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AUTOINJECTORS MARKET
• 13.3 REVENUE ANALYSIS
  • 13.3.1 REVENUE ANALYSIS: AUTOINJECTOR DEVICES MARKET
  • 13.3.2 REVENUE ANALYSIS: AUTOINJECTOR FINISHED FORMULATIONS MARKET
• 13.4 MARKET SHARE ANALYSIS
  • 13.4.1 MARKET SHARE ANALYSIS: AUTOINJECTOR DEVICES MARKET
  • 13.4.2 MARKET SHARE ANALYSIS: AUTOINJECTOR FINISHED FORMULATIONS MARKET
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 13.5.1 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 13.5.1.1 Stars
    • 13.5.1.2 Emerging leaders
    • 13.5.1.3 Pervasive players
    • 13.5.1.4 Participants
  • 13.5.2 AUTOINJECTOR FINISHED FORMULATIONS MARKET: COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 13.5.2.1 Stars
    • 13.5.2.2 Emerging leaders
    • 13.5.2.3 Pervasive players
    • 13.5.2.4 Participants
  • 13.5.3 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.5.3.1 Company footprint
    • 13.5.3.2 Region footprint
    • 13.5.3.3 Usage footprint
    • 13.5.3.4 Volume footprint
    • 13.5.3.5 Route of administration footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 13.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.7.1 FINANCIAL METRICS
  • 13.7.2 COMPANY VALUATION
• 13.8 BRAND/PRODUCT COMPARISON
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS
• 13.10 DEVICES FOR LARGE-VOLUME FORMULATIONS
• 13.11 DEVICES FOR HIGHLY VISCOUS FORMULATIONS
• 13.12 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET

14 COMPANY PROFILES

• 14.1 KEY PLAYERS: AUTOINJECTOR DEVICES MARKET
  • 14.1.1 SHL MEDICAL AG
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches
      • 14.1.1.3.2 Deals
      • 14.1.1.3.3 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 YPSOMED AG
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches
      • 14.1.2.3.2 Deals
      • 14.1.2.3.3 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 BECTON, DICKINSON AND COMPANY (BD)
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Deals
      • 14.1.3.3.2 Other developments
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 RECIPHARM AB
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
  • 14.1.5 WEST PHARMACEUTICAL SERVICES, INC.
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Expansions
  • 14.1.6 PHILLIPS-MEDISIZE
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches
  • 14.1.7 HALOZYME, INC.
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
  • 14.1.8 OWEN MUMFORD LTD.
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches
      • 14.1.8.3.2 Deals
      • 14.1.8.3.3 Expansions
• 14.2 KEY PLAYERS: AUTOINJECTOR FINISHED FORMULATIONS MARKET
  • 14.2.1 ABBVIE INC.
    • 14.2.1.1 Business overview
    • 14.2.1.2 Products offered
    • 14.2.1.3 Recent developments
      • 14.2.1.3.1 Product launches and approvals
  • 14.2.2 ELI LILLY AND COMPANY
    • 14.2.2.1 Business overview
    • 14.2.2.2 Products offered
    • 14.2.2.3 Recent developments
      • 14.2.2.3.1 Product approvals
      • 14.2.2.3.2 Deals
  • 14.2.3 AMGEN INC.
    • 14.2.3.1 Business overview
    • 14.2.3.2 Products offered
    • 14.2.3.3 Recent developments
      • 14.2.3.3.1 Product launches
  • 14.2.4 NOVO NORDISK A/S
    • 14.2.4.1 Business overview
    • 14.2.4.2 Products offered
    • 14.2.4.3 Recent developments
      • 14.2.4.3.1 Product approvals
      • 14.2.4.3.2 Deals
      • 14.2.4.3.3 Expansions
      • 14.2.4.3.4 Other developments
  • 14.2.5 JOHNSON & JOHNSON SERVICES, INC.
    • 14.2.5.1 Business overview
    • 14.2.5.2 Products offered
  • 14.2.6 SANOFI
    • 14.2.6.1 Business overview
    • 14.2.6.2 Products offered
  • 14.2.7 GSK PLC
    • 14.2.7.1 Business overview
    • 14.2.7.2 Products offered
    • 14.2.7.3 Recent developments
      • 14.2.7.3.1 Product approvals
• 14.3 OTHER PLAYERS
  • 14.3.1 GERRESHEIMER AG
  • 14.3.2 HASELMEIER
  • 14.3.3 OVAL MEDICAL TECHNOLOGIES LTD.
  • 14.3.4 KALEO, INC.
  • 14.3.5 SOLTEAM INCORPORATION CO., LTD.
  • 14.3.6 ELCAM DRUG DELIVERY DEVICES
  • 14.3.7 CROSSJECT
  • 14.3.8 JABIL INC.
  • 14.3.9 CONGRUENCE MEDICAL SOLUTIONS LLC
  • 14.3.10 MIDAS PHARMA GMBH

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS

List of Tables

• TABLE 1 AUTOINJECTORS MARKET: INCLUSIONS & EXCLUSIONS
• TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON AUTOINJECTORS MARKET
• TABLE 3 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS IN US AND EUROPE, 2020-2024
• TABLE 4 PATENT EXPIRY OF KEY BIOLOGICS
• TABLE 5 LIST OF KEY AUTOINJECTOR DEVICE PROVIDERS
• TABLE 6 LIST OF KEY AUTOINJECTOR FINISHED FORMULATION PRODUCT PROVIDERS
• TABLE 7 LIST OF KEY END USERS
• TABLE 8 LIST OF KEY REGULATORY BODIES
• TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 13 AUTOINJECTORS MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 14 IMPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS), 2021-2023 (USD MILLION)
• TABLE 15 EXPORT DATA FOR PRODUCTS (INCLUDING AUTOINJECTORS), 2021-2023 (USD MILLION)
• TABLE 16 LIST OF ADVANTAGES AND DISADVANTAGES OF AUTOINJECTOR TECHNOLOGIES
• TABLE 17 NUMBER OF PATENTS FILED IN AUTOINJECTORS MARKET, 2014-2024
• TABLE 18 TOP 10 PATENT OWNERS IN US IN AUTOINJECTORS MARKET, 2014-2024
• TABLE 19 DETAILED ANALYSIS OF KEY PATENTS IN AUTOINJECTORS MARKET, 2022-2024
• TABLE 20 INDICATIVE PRICING OF FINISHED FORMULATION PRODUCTS, BY KEY PLAYER, 2023
• TABLE 21 INDICATIVE PRICING ANALYSIS OF THERAPY AREAS FOR AUTOINJECTOR FINISHED FORMULATIONS, BY REGION, 2023
• TABLE 22 AUTOINJECTORS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024-DECEMBER 2025
• TABLE 23 AUTOINJECTOR DEVICES MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
• TABLE 24 AUTOINJECTOR FINISHED FORMULATIONS MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
• TABLE 25 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 26 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (MILLION UNITS)
• TABLE 27 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 28 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 29 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (MILLION UNITS)
• TABLE 30 NORTH AMERICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 31 EUROPE: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 32 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 33 LATIN AMERICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 34 MIDDLE EAST & AFRICA: DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 35 DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 36 NORTH AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 37 EUROPE: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 38 ASIA PACIFIC: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 39 LATIN AMERICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 40 MIDDLE EAST & AFRICA: DISPOSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 41 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 42 REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (MILLION UNITS)
• TABLE 43 NORTH AMERICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 44 EUROPE: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 45 ASIA PACIFIC: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 46 LATIN AMERICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 47 MIDDLE EAST & AFRICA: REUSABLE AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 48 REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 49 NORTH AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 50 EUROPE: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 51 ASIA PACIFIC: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 52 LATIN AMERICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 53 MIDDLE EAST & AFRICA: REUSABLE AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 54 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 55 AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (MILLION UNITS)
• TABLE 56 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 57 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 58 MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (MILLION UNITS)
• TABLE 59 NORTH AMERICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 60 EUROPE: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 61 ASIA PACIFIC: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 62 LATIN AMERICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 63 MIDDLE EAST & AFRICA: MANUAL AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 64 MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 65 NORTH AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 66 EUROPE: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 67 ASIA PACIFIC: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 68 LATIN AMERICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 69 MIDDLE EAST & AFRICA: MANUAL AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 70 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 71 AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (MILLION UNITS)
• TABLE 72 NORTH AMERICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 73 EUROPE: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 74 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 75 LATIN AMERICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 76 MIDDLE EAST & AFRICA: AUTOMATIC AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 77 AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 78 NORTH AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 79 EUROPE: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 80 ASIA PACIFIC: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 81 LATIN AMERICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 82 MIDDLE EAST & AFRICA: AUTOMATIC AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 83 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 84 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (MILLION UNITS)
• TABLE 85 AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2030 (USD MILLION)
• TABLE 86 AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2030 (MILLION UNITS)
• TABLE 87 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 88 EUROPE: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 89 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 90 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 91 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2030 (USD MILLION)
• TABLE 92 AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 93 AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, 2022-2030 (MILLION UNITS)
• TABLE 94 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 95 EUROPE: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 96 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 97 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 98 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY REGION, 2022-2030 (USD MILLION)
• TABLE 99 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 100 AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (MILLION UNITS)
• TABLE 101 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 102 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 103 AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022-2030 (MILLION UNITS)
• TABLE 104 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 105 EUROPE: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 106 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 107 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 108 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 109 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 110 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 111 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 112 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 113 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 114 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 115 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 116 AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2022-2030 (MILLION UNITS)
• TABLE 117 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 118 EUROPE: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 119 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 120 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 121 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR DIABETES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 122 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 123 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 124 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 125 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 126 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 127 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR DIABETES, BY REGION, 2022-2030 (USD MILLION)
• TABLE 128 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 129 AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022-2030 (MILLION UNITS)
• TABLE 130 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 131 EUROPE: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 132 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 133 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 134 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 135 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 136 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 137 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 138 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 139 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 140 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 141 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 142 AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2022-2030 (MILLION UNITS)
• TABLE 143 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 144 EUROPE: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 145 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 146 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 147 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR ANAPHYLAXIS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 148 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 149 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 150 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 151 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 152 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 153 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR ANAPHYLAXIS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 154 AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY REGION, 2022-2030 (USD MILLION)
• TABLE 155 AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY REGION, 2022-2030 (MILLION UNITS)
• TABLE 156 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 157 EUROPE: AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 158 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 159 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 160 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR OBESITY, BY REGION, 2022-2030 (USD MILLION)
• TABLE 161 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY REGION, 2022-2030 (USD MILLION)
• TABLE 162 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 163 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 164 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 165 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 166 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OBESITY, BY REGION, 2022-2030 (USD MILLION)
• TABLE 167 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 168 AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2030 (MILLION UNITS)
• TABLE 169 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 170 EUROPE: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 171 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 172 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 173 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 174 AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 175 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 176 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 177 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 178 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 179 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 180 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022-2030 (USD MILLION)
• TABLE 181 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022-2030 (MILLION UNITS)
• TABLE 182 UP TO 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 183 UP TO 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (MILLION UNITS)
• TABLE 184 ABOVE 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 185 ABOVE 3ML VOLUME AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (MILLION UNITS)
• TABLE 186 AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 187 AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 188 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 189 EUROPE: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 190 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 191 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 192 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 193 AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 194 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 195 EUROPE: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 196 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 197 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 198 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 199 AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 200 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 201 EUROPE: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 202 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 203 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 204 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET FOR AMBULATORY CARE SETTINGS, BY REGION, 2022-2030 (USD MILLION)
• TABLE 205 AUTOINJECTOR DEVICES MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 206 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 207 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 208 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 209 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 210 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 211 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 212 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022-2030 (USD MILLION)
• TABLE 213 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 214 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 215 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 216 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 217 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 218 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 219 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2022-2030 (USD MILLION)
• TABLE 220 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 221 AUTOINJECTORS APPROVED BY US FDA, 2018-2024
• TABLE 222 US: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 223 US: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 224 US: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 225 US: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 226 US: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 227 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 228 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 229 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 230 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 231 US: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 232 CANADA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 233 CANADA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 234 CANADA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 235 CANADA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 236 CANADA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 237 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 238 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 239 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 240 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 241 CANADA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 242 EUROPE: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 243 EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 244 EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 245 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 246 EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 247 EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022-2030 (USD MILLION)
• TABLE 248 EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 249 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 250 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 251 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 252 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 253 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 254 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2022-2030 (USD MILLION)
• TABLE 255 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 256 GERMANY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 257 GERMANY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 258 GERMANY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 259 GERMANY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 260 GERMANY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 261 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 262 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 263 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 264 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 265 GERMANY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 266 UK: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 267 UK: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 268 UK: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 269 UK: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 270 UK: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 271 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 272 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 273 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 274 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 275 UK: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 276 FRANCE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 277 FRANCE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 278 FRANCE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 279 FRANCE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 280 FRANCE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 281 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 282 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 283 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 284 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 285 FRANCE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 286 ITALY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 287 ITALY: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 288 ITALY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 289 ITALY: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 290 ITALY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 291 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 292 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 293 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 294 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 295 ITALY: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 296 SPAIN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 297 SPAIN: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 298 SPAIN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 299 SPAIN: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 300 SPAIN: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 301 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 302 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 303 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 304 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 305 SPAIN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 306 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 307 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 308 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 309 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 310 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 311 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 312 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 313 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 314 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 315 REST OF EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 316 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 317 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 318 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 319 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 320 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 321 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022-2030 (USD MILLION)
• TABLE 322 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 323 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 324 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 325 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 326 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 327 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 328 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2022-2030 (USD MILLION)
• TABLE 329 ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 330 JAPAN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 331 JAPAN: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 332 JAPAN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 333 JAPAN: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 334 JAPAN: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 335 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 336 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 337 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 338 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 339 JAPAN: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 340 CHINA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 341 CHINA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 342 CHINA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 343 CHINA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 344 CHINA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 345 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 346 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 347 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 348 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 349 CHINA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 350 INDIA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 351 INDIA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 352 INDIA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 353 INDIA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 354 INDIA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 355 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 356 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 357 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 358 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 359 INDIA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 360 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 361 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 362 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 363 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 364 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 365 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 366 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 367 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 368 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 369 SOUTH KOREA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 370 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 371 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 372 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 373 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 374 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 375 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 376 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 377 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 378 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 379 REST OF ASIA PACIFIC: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 380 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 381 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 382 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 383 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 384 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 385 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022-2030 (USD MILLION)
• TABLE 386 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 387 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 388 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 389 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 390 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 391 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 392 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2022-2030 (USD MILLION)
• TABLE 393 LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 394 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 395 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 396 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 397 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 398 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 399 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 400 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 401 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 402 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 403 BRAZIL: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 404 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 405 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 406 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 407 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 408 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 409 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 410 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 411 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 412 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 413 REST OF LATIN AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 414 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 415 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 416 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 417 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 418 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 419 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2022-2030 (USD MILLION)
• TABLE 420 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 421 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 422 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 423 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 424 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 425 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 426 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY VOLUME, 2022-2030 (USD MILLION)
• TABLE 427 MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 428 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 429 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 430 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 431 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 432 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 433 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 434 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 435 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 436 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 437 GCC COUNTRIES: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 438 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 439 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 440 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 441 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 442 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 443 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2022-2030 (USD MILLION)
• TABLE 444 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 445 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
• TABLE 446 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY THERAPY AREA, 2022-2030 (USD MILLION)
• TABLE 447 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 448 OVERVIEW OF STRATEGIES DEPLOYED BY KEY AUTOINJECTOR DEVICE MANUFACTURING COMPANIES
• TABLE 449 AUTOINJECTOR DEVICES MARKET: DEGREE OF COMPETITION
• TABLE 450 AUTOINJECTOR FINISHED FORMULATIONS MARKET: DEGREE OF COMPETITION
• TABLE 451 AUTOINJECTOR DEVICES MARKET: REGION FOOTPRINT
• TABLE 452 AUTOINJECTOR FINISHED FORMULATIONS MARKET: REGION FOOTPRINT
• TABLE 453 AUTOINJECTOR DEVICES MARKET: USAGE FOOTPRINT
• TABLE 454 AUTOINJECTOR FINISHED FORMULATIONS MARKET: USAGE FOOTPRINT
• TABLE 455 AUTOINJECTOR DEVICES MARKET: VOLUME FOOTPRINT
• TABLE 456 AUTOINJECTOR DEVICES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
• TABLE 457 AUTOINJECTOR FINISHED FORMULATIONS MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
• TABLE 458 AUTOINJECTORS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 459 AUTOINJECTORS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS
• TABLE 460 AUTOINJECTORS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2024
• TABLE 461 AUTOINJECTORS MARKET: DEALS, JANUARY 2021-JULY 2024
• TABLE 462 AUTOINJECTORS MARKET: EXPANSIONS, JANUARY 2021-JULY 2024
• TABLE 463 AUTOINJECTORS MARKET: DEVICES FOR LARGE-VOLUME FORMULATIONS
• TABLE 464 AUTOINJECTORS MARKET: DEVICES FOR HIGHLY VISCOUS FORMULATIONS
• TABLE 465 FORMULATION AND DEVICE TECHNOLOGIES ENABLING SUBCUTANEOUS DELIVERY OF HIGH-DOSE BIOLOGICS
• TABLE 466 SHL MEDICAL AG: COMPANY OVERVIEW
• TABLE 467 SHL MEDICAL AG: PRODUCTS OFFERED
• TABLE 468 SHL MEDICAL AG: PRODUCT LAUNCHES, JANUARY 2021-JULY 2024
• TABLE 469 SHL MEDICAL AG: DEALS, JANUARY 2021-JULY 2024
• TABLE 470 SHL MEDICAL AG: EXPANSIONS, JANUARY 2021-JULY 2024
• TABLE 471 YPSOMED AG: COMPANY OVERVIEW
• TABLE 472 YPSOMED AG: PRODUCTS OFFERED
• TABLE 473 YPSOMED AG: PRODUCT LAUNCHES, JANUARY 2021-JULY 2024
• TABLE 474 YPSOMED AG: DEALS, JANUARY 2021-JULY 2024
• TABLE 475 YPSOMED AG: EXPANSIONS, JANUARY 2021-JULY 2024
• TABLE 476 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
• TABLE 477 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED
• TABLE 478 BECTON, DICKINSON AND COMPANY (BD): DEALS, JANUARY 2021-JULY 2024
• TABLE 479 BECTON, DICKINSON AND COMPANY (BD): OTHER DEVELOPMENTS, JANUARY 2021-JULY 2024
• TABLE 480 RECIPHARM AB: COMPANY OVERVIEW
• TABLE 481 RECIPHARM AB: PRODUCTS OFFERED
• TABLE 482 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW
• TABLE 483 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED
• TABLE 484 WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS, JANUARY 2021-JULY 2024
• TABLE 485 PHILLIPS-MEDISIZE: COMPANY OVERVIEW
• TABLE 486 PHILLIPS-MEDISIZE: PRODUCTS OFFERED
• TABLE 487 PHILLIPS-MEDISIZE: PRODUCT LAUNCHES, JANUARY 2021-JULY 2024
• TABLE 488 HALOZYME, INC.: COMPANY OVERVIEW
• TABLE 489 HALOZYME, INC.: PRODUCTS OFFERED
• TABLE 490 OWEN MUMFORD LTD.: COMPANY OVERVIEW
• TABLE 491 OWEN MUMFORD LTD.: PRODUCTS OFFERED
• TABLE 492 OWEN MUMFORD LTD.: PRODUCT LAUNCHES, JANUARY 2021-JULY 2024
• TABLE 493 OWEN MUMFORD LTD.: DEALS, JANUARY 2021-JULY 2024
• TABLE 494 OWEN MUMFORD LTD.: EXPANSIONS, JANUARY 2021-JULY 2024
• TABLE 495 ABBVIE INC.: COMPANY OVERVIEW
• TABLE 496 ABBVIE INC.: PRODUCTS OFFERED
• TABLE 497 ABBVIE INC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-JULY 2024
• TABLE 498 ELI LILLY AND COMPANY: COMPANY OVERVIEW
• TABLE 499 ELI LILLY AND COMPANY: PRODUCTS OFFERED
• TABLE 500 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2021-JULY 2024
• TABLE 501 ELI LILLY AND COMPANY: DEALS, JANUARY 2021-JULY 2024
• TABLE 502 AMGEN INC.: COMPANY OVERVIEW
• TABLE 503 AMGEN INC.: PRODUCTS OFFERED
• TABLE 504 AMGEN INC.: PRODUCT LAUNCHES, JANUARY 2021-JULY 2024
• TABLE 505 NOVO NORDISK A/S: COMPANY OVERVIEW
• TABLE 506 NOVO NORDISK A/S: PRODUCTS OFFERED
• TABLE 507 NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2021-JULY 2024
• TABLE 508 NOVO NORDISK A/S: DEALS, JANUARY 2021-JULY 2024
• TABLE 509 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2021-JULY 2024
• TABLE 510 NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2021-JULY 2024
• TABLE 511 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
• TABLE 512 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
• TABLE 513 SANOFI: COMPANY OVERVIEW
• TABLE 514 SANOFI: PRODUCTS OFFERED
• TABLE 515 GSK PLC: COMPANY OVERVIEW
• TABLE 516 GSK PLC: PRODUCTS OFFERED
• TABLE 517 GSK PLC: PRODUCT APPROVALS, JANUARY 2021-JULY 2024
• TABLE 518 GERRESHEIMER AG: COMPANY OVERVIEW
• TABLE 519 HASELMEIER: COMPANY OVERVIEW
• TABLE 520 OVAL MEDICAL TECHNOLOGIES LTD.: COMPANY OVERVIEW
• TABLE 521 KALEO, INC.: COMPANY OVERVIEW
• TABLE 522 SOLTEAM INCORPORATION CO., LTD.: COMPANY OVERVIEW
• TABLE 523 ELCAM DRUG DELIVERY DEVICES: COMPANY OVERVIEW
• TABLE 524 CROSSJECT: COMPANY OVERVIEW
• TABLE 525 JABIL INC.: COMPANY OVERVIEW
• TABLE 526 CONGRUENCE MEDICAL SOLUTIONS LLC: COMPANY OVERVIEW
• TABLE 527 MIDAS PHARMA GMBH: COMPANY OVERVIEW

List of Figures

• FIGURE 1 AUTOINJECTORS MARKET: SEGMENTS CONSIDERED
• FIGURE 2 AUTOINJECTORS MARKET: YEARS CONSIDERED
• FIGURE 3 AUTOINJECTORS MARKET: RESEARCH DESIGN
• FIGURE 4 AUTOINJECTORS MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS)
• FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
• FIGURE 6 MARKET SIZE ESTIMATION FOR AUTOINJECTOR DEVICES: REVENUE SHARE ANALYSIS
• FIGURE 7 ILLUSTRATIVE EXAMPLE OF YPSOMED AG: REVENUE SHARE ANALYSIS (2023)
• FIGURE 8 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
• FIGURE 9 MARKET SIZE ESTIMATION FOR AUTOINJECTOR FINISHED FORMULATIONS: REVENUE SHARE ANALYSIS
• FIGURE 10 ILLUSTRATIVE EXAMPLE OF ABBVIE INC.: REVENUE SHARE ANALYSIS (2023)
• FIGURE 11 AUTOINJECTORS MARKET: MARKET VALIDATION FROM PRIMARY EXPERTS
• FIGURE 12 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
• FIGURE 13 AUTOINJECTOR DEVICES MARKET SIZE ESTIMATION
• FIGURE 14 AUTOINJECTOR DEVICES MARKET: CAGR PROJECTIONS (2024-2030)
• FIGURE 15 AUTOINJECTOR FINISHED FORMULATIONS MARKET: CAGR PROJECTIONS (2024-2030)
• FIGURE 16 DATA TRIANGULATION METHODOLOGY
• FIGURE 17 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024 VS. 2030 (USD MILLION)
• FIGURE 18 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024 VS. 2030 (MILLION UNITS)
• FIGURE 19 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY USAGE, 2024 VS. 2030 (USD BILLION)
• FIGURE 20 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2030 (USD MILLION)
• FIGURE 21 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2030 (USD BILLION)
• FIGURE 22 AUTOINJECTOR DEVICES MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
• FIGURE 23 AUTOINJECTOR FINISHED FORMULATIONS MARKET, BY END USER, 2024 VS. 2030 (USD BILLION)
• FIGURE 24 AUTOINJECTOR DEVICES MARKET: REGIONAL SNAPSHOT
• FIGURE 25 AUTOINJECTOR FINISHED FORMULATIONS MARKET: REGIONAL SNAPSHOT
• FIGURE 26 INCREASING REGULATORY APPROVALS FOR FINISHED FORMULATION DRUGS TO PROPEL MARKET GROWTH
• FIGURE 27 US AND DISPOSABLE AUTOINJECTORS DOMINATED MARKET IN 2023
• FIGURE 28 US AND SUBCUTANEOUS ROUTE OF ADMINISTRATION COMMANDED LARGER MARKET SHARE IN 2023
• FIGURE 29 RHEUMATOID ARTHRITIS TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 30 MANUAL AUTOINJECTORS ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
• FIGURE 31 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2030
• FIGURE 32 ASIA PACIFIC TO COMMAND HIGHEST CAGR DURING STUDY PERIOD
• FIGURE 33 AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 34 REVENUE SHIFT AND POCKETS FOR AUTOINJECTOR PROVIDERS
• FIGURE 35 AUTOINJECTOR DEVICES MARKET: VALUE CHAIN ANALYSIS
• FIGURE 36 AUTOINJECTOR FINISHED FORMULATIONS MARKET: VALUE CHAIN ANALYSIS
• FIGURE 37 AUTOINJECTORS MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 38 AUTOINJECTORS MARKET: ECOSYSTEM MAP
• FIGURE 39 AUTOINJECTORS MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 40 TOTAL NUMBER OF PATENTS GRANTED, 2014-2023
• FIGURE 41 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2024
• FIGURE 42 REGIONAL ANALYSIS OF PATENTS GRANTED, 2014-2024
• FIGURE 43 AVERAGE SELLING PRICE TREND, BY PRODUCT TYPE (2021-2023)
• FIGURE 44 AVERAGE SELLING PRICE TREND, BY USAGE (2023)
• FIGURE 45 KEY STAKEHOLDERS IN BUYING PROCESS FOR PHARMACEUTICAL COMPANIES (AUTOINJECTOR DEVICES)
• FIGURE 46 KEY STAKEHOLDERS IN BUYING PROCESS FOR HOSPITALS (AUTOINJECTOR FINISHED FORMULATIONS)
• FIGURE 47 KEY BUYING CRITERIA FOR AUTOINJECTOR DEVICES AMONG END USERS
• FIGURE 48 KEY BUYING CRITERIA FOR AUTOINJECTOR FINISHED FORMULATIONS AMONG END USERS
• FIGURE 49 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SNAPSHOT (2023)
• FIGURE 50 NORTH AMERICA: AUTOINJECTOR FINISHED FORMULATIONS MARKET SNAPSHOT (2023)
• FIGURE 51 EUROPE: AUTOINJECTOR DEVICES MARKET SNAPSHOT
• FIGURE 52 EUROPE: AUTOINJECTOR FINISHED FORMULATIONS MARKET SNAPSHOT
• FIGURE 53 REVENUE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET (2021-2023)
• FIGURE 54 REVENUE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR FINISHED FORMULATIONS MARKET (2021-2023)
• FIGURE 55 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET (2023)
• FIGURE 56 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR FINISHED FORMULATIONS MARKET (2023)
• FIGURE 57 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 58 AUTOINJECTOR FINISHED FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 59 AUTOINJECTOR DEVICES MARKET: COMPANY FOOTPRINT
• FIGURE 60 AUTOINJECTOR FINISHED FORMULATIONS MARKET: COMPANY FOOTPRINT
• FIGURE 61 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 62 EV/EBITDA OF KEY VENDORS
• FIGURE 63 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 64 AUTOINJECTOR DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 65 YPSOMED AG: COMPANY SNAPSHOT (2023)
• FIGURE 66 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2023)
• FIGURE 67 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 68 HALOZYME, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 69 ABBVIE INC.: COMPANY SNAPSHOT (2023)
• FIGURE 70 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2023)
• FIGURE 71 AMGEN INC.: COMPANY SNAPSHOT (2023)
• FIGURE 72 NOVO NORDISK A/S: COMPANY SNAPSHOT (2023)
• FIGURE 73 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2023)
• FIGURE 74 SANOFI: COMPANY SNAPSHOT (2023)
• FIGURE 75 GSK PLC: COMPANY SNAPSHOT (2023)